Medicines Monitoring Unit, University of Dundee, Dundee DD1 9SY, UK.
BMJ. 2012 Jul 13;345:e4447. doi: 10.1136/bmj.e4447.
To investigate whether exposure to spironolactone treatment affects the risk of incident breast cancer in women over 55 years of age.
Retrospective, matched cohort study.
General Practice Research Database, a primary care anonymised database representative of the general population in the United Kingdom.
1,290,625 female patients, older than 55 years and with no history of breast cancer, from 557 general practices with a total follow-up time of 8.4 million patient years. We excluded patients with poor quality data and those with no contacts with their general practitioner after their current registration date.
Exposed cohort included women who received at least two prescriptions of spironolactone after age 55 years, who were followed up from the first prescription (index date). We randomly selected two unexposed female controls for every exposed patient, matched by practice, year of birth, and socioeconomic scores (if information was available), and followed up from the same date.
New cases of breast cancer, using Read codes to confirm diagnoses.
Index dates for study patients ranged from 1987 to 2010, and 29,491 new cases of breast cancer were recorded in the study population (incidence rate 0.35% per year). The exposed cohort of 28,032 patients and control cohort of 55,961 patients had unadjusted incidence rates of 0.39% and 0.38% per year, respectively, over a mean follow-up time of 4.1 years. Time-to-event analysis, adjusting for potential risk factors, provided no evidence of an increased incidence of breast cancer in patients exposed to spironolactone (hazard ratio 0.99, 95% confidence interval 0.87 to 1.12).
These data suggest that the long term management of cardiovascular conditions with spironolactone does not increase the risk of breast cancer in women older than 55 years with no history of the disease.
研究螺内酯治疗暴露是否会增加 55 岁以上女性乳腺癌发病风险。
回顾性、匹配队列研究。
一般实践研究数据库,一个英国初级保健匿名数据库,代表了一般人群。
来自 557 家全科诊所的 1290625 名 55 岁以上、无乳腺癌病史的女性患者,总随访时间为 840 万患者年。我们排除了数据质量差的患者和在当前登记日期后与全科医生无联系的患者。
暴露组包括 55 岁后至少接受两次螺内酯处方的女性患者,随访从第一次处方(索引日期)开始。我们随机选择了每一位暴露患者的两名未暴露女性对照者,按照实践、出生年份和社会经济评分(如果有信息)进行匹配,并从同一日期开始随访。
使用 Read 编码确认诊断的新乳腺癌病例。
研究患者的索引日期范围为 1987 年至 2010 年,研究人群中记录了 29491 例新乳腺癌病例(年发病率为 0.35%)。暴露组 28032 例患者和对照组 55961 例患者未经调整的年发病率分别为 0.39%和 0.38%,平均随访时间为 4.1 年。调整潜在危险因素的时间事件分析未发现暴露于螺内酯的患者乳腺癌发病率增加(风险比 0.99,95%置信区间 0.87 至 1.12)。
这些数据表明,长期使用螺内酯治疗心血管疾病不会增加无乳腺癌病史的 55 岁以上女性患乳腺癌的风险。